Discovering New Medicines and New Ways to Pay For Them

While the rest of the health care system is moving toward paying for value, payments for drugs largely continue to be stuck in a 20th century construct that focuses on price, regardless of the health outcomes of each patient. This lack of payment innovation is particularly damaging in an era where on the horizon new [...]

2017-07-03T22:27:07-06:00January 29th, 2016|Publications, Viewpoints|

Are Biopharmaceutical Budget Caps Good Public Policy?

Medical innovation has generated significant gains in health over the past decades, but these advances have been accompanied by rapid growth in healthcare spending. Faced with a growing number of high-cost but high impact innovations, some have argued to constrain prices for new therapies – especially through global caps on pharmaceutical spending and limits on [...]

2017-07-04T23:44:13-06:00January 12th, 2016|Publications, Viewpoints|

Measuring the Value of Prescription Drugs

Escalating drug prices have alarmed physicians and the American public and led to calls for government price controls. Less visibly, they have also spawned a flurry of private-sector initiatives designed to help physicians, payers, and patients understand the value of new therapies and thus make better choices about their use. Programs recently introduced or advanced [...]

2017-07-03T23:14:37-06:00December 31st, 2015|Publications, Research|

Moving Beyond Price-Per-Dose in the Pharmaceutical Industry

Many patients today are missing out on the benefits of therapies for financial reasons. The problem here is our current model of pharmaceutical pricing, which threatens to deprive patients of current beneficial therapies and other breakthroughs to come. For decades, the vast majority of drug manufacturers and payers have relied on pricing per dose, be [...]

2017-07-03T23:25:00-06:00September 30th, 2015|Publications, Viewpoints|

Understanding Health Care’s Short-Termism Problem

The meaning of "value" varies by each stakeholder and is thereore the least well understood. Drs. Chandra and Goldman discuss that the right way to think about value in health care delivery is a stream of benefiƒts accrued over a lifetime that is attractive relative to the price paid to acquire them. Using examples with [...]

2017-07-03T22:54:25-06:00September 28th, 2015|Publications, Viewpoints|

The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations

The PRISMA statement is a reporting guideline designed to improve the completeness of reporting of systematic reviews and meta-analyses. Authors have used this guideline worldwide to prepare their reviews for publication. In the past, these reports typically compared 2 treatment alternatives. With the evolution of systematic reviews that compare multiple treatments, some of them only [...]

2017-07-03T23:12:54-06:00June 2nd, 2015|Publications, Research|

It’s Time for Value-Based Payment in Oncology

Value-based health care has risen to the top of the health policy agenda, as public and private payers search for ways to improve outcomes. The value principle—reimbursing hospitals, physicians, and other health care providers for quality or quality improvement that also help lower costs—aligns incentives between payers and providers. It’s time to apply this principle [...]

2017-07-03T23:34:35-06:00April 28th, 2015|Publications, Viewpoints|

Reforming Medicare’s Dialysis Payment Policies: Implications for Patients with Secondary Hyperparathyroidism

Expanding services covered by a “bundled payment” can also expand variation in the costs of treating patients under the bundle. In this article, Charu Gupta et al.explore this topic further using the Medicare dialysis program as an example. Source: Health Services Research

2017-07-03T23:01:17-06:00July 14th, 2014|Publications, Research|

Reforming Medicare’s Dialysis Payment Policies: Implications for Patients with Secondary Hyperparathyroidism

Expanding services covered by a “bundled payment” can also expand variation in the costs of treating patients under the bundle. In this article, Charu Gupta et al.explore this topic further using the Medicare dialysis program as an example. Source: Health Services Research

2017-07-03T23:16:18-06:00July 7th, 2014|Publications, Research|

Indirect Treatment Comparison/Network Meta-Analysis Study Questionnaire to Assess Relevance and Credibility to Inform Health Care Decision Making: An ISPOR-AMCP-NPC Good Practice Task Force Report

Despite the great realized or potential value of network meta-analysis of randomized controlled trial evidence to inform health care decision making, many decision makers might not be familiar with these techniques. The Task Force developed a consensus-based 26-item questionnaire to help decision makers assess the relevance and the credibility of indirect treatment comparisons and network [...]

2017-07-03T22:31:22-06:00March 15th, 2014|Publications, Research|